| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Olson and DeAngelis) and Epidemiology and Biostatistics (E. Riedel), Memorial Sloan-Kettering Cancer Center, New York, NY.
Address correspondence and reprint requests to Dr. Lisa M. DeAngelis, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.
BACKGROUND: Low-grade oligodendrogliomas and mixed gliomas can be indolent and remain unchanged for years. Optimal timing and effectiveness of initial treatment is uncertain and therapy can be associated with toxicity.
METHODS: Retrospective review of patients diagnosed between 1979 and 1997 with low-grade oligodendroglioma or mixed glioma. Time to progression, survival, prognostic factors, and treatment toxicities were evaluated.
RESULTS: A total of 106 patients (77 oligodendroglioma, 29 mixed glioma) were identified; median age was 36.7 years. Initial presenting symptoms were seizures in 76 (72%) and headache in 11 (10%); tumor was diagnosed as an incidental finding in five patients. Tumor progression was diagnosed in 72 patients (68%). Overall median time to progression (MTTP) was 5.0 years (range 0.5 to 14.2). Median overall survival (OS) was 16.7 years. No prognostic factors reached statistical significance. MTTP and OS were not significantly affected by treatment. Of 62 patients who received radiation therapy, 9 (15%) developed radiation necrosis and 13 developed radiation therapy–related cognitive changes, requiring ventriculoperitoneal shunting in six. Significant myelosuppression was seen in 35 of 76 (46%) patients treated with chemotherapy.
CONCLUSIONS: Low-grade oligodendroglioma and mixed glioma have a long median overall survival. There were no apparent differences in either immediate versus deferred treatment or choice of initial therapy on disease-free or overall survival. Chemotherapy was associated with significant acute toxicity in almost one half of patients; radiation therapy produced late neurotoxicity in one third, justifying deferred treatment until clinically necessary.
Key words: Oligodendroglioma—Mixed glioma—Outcome—Chemotherapy—Radiation therapy
This article has been cited by other articles:
|
|
 |
|
  W. P. Mason and J. G. Cairncross Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas Neurology, July 29, 2008; 71(5): 365 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Smith, E. F. Chang, K. R. Lamborn, S. M. Chang, M. D. Prados, S. Cha, T. Tihan, S. VandenBerg, M. W. McDermott, and M. S. Berger Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas J. Clin. Oncol., March 10, 2008; 26(8): 1338 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bosma, L. Douw, F. Bartolomei, J. J. Heimans, B. W. van Dijk, T. J. Postma, C. J. Stam, J. C. Reijneveld, and M. Klein Synchronized brain activity and neurocognitive function in patients with low-grade glioma: A magnetoencephalography study Neuro-oncol, January 1, 2008; 10(5): 734 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bosma, M. J. Vos, J. J. Heimans, M. J.B. Taphoorn, N. K. Aaronson, T. J. Postma, H. M. van der Ploeg, M. Muller, W. P. Vandertop, Ben. J. Slotman, et al. The course of neurocognitive functioning in high-grade glioma patients Neuro-oncol, January 1, 2007; 9(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Puputti, O. Tynninen, H. Sihto, T. Blom, H. Maenpaa, J. Isola, A. Paetau, H. Joensuu, and N. N. Nupponen Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas Mol. Cancer Res., December 1, 2006; 4(12): 927 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Grier and T. Batchelor Low-grade gliomas in adults. Oncologist, June 1, 2006; 11(6): 681 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Lang and M. R. Gilbert Diffusely Infiltrative Low-Grade Gliomas in Adults J. Clin. Oncol., March 10, 2006; 24(8): 1236 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koeller and E. J. Rushing From the Archives of the AFIP: Oligodendroglioma and Its Variants: Radiologic-Pathologic Correlation RadioGraphics, November 1, 2005; 25(6): 1669 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Higuchi, Y. Iwadate, and A. Yamaura Treatment of low-grade oligodendroglial tumors without radiotherapy Neurology, December 28, 2004; 63(12): 2384 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, et al. Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions J. Clin. Oncol., August 1, 2004; 22(15): 3133 - 3138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lebrun, D. Fontaine, A. Ramaioli, F. Vandenbos, S. Chanalet, M. Lonjon, J. F. Michiels, V. Bourg, P. Paquis, M. Chatel, et al. Long-term outcome of oligodendrogliomas Neurology, May 25, 2004; 62(10): 1783 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Naugle, T. D. Duncan, and G. P. Grice Oligoastrocytoma RadioGraphics, March 1, 2004; 24(2): 598 - 600. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brada, L. Viviers, C. Abson, F. Hines, J. Britton, S. Ashley, S. Sardell, D. Traish, A. Gonsalves, P. Wilkins, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas Ann. Onc., December 1, 2003; 14(12): 1715 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Perry Pathology of low-grade gliomas: An update of emerging concepts Neuro-oncol, July 1, 2003; 5(3): 168 - 178. [Abstract] [PDF]
|
|
|
|
|
|
M. van den Bent, O.-L. Chinot, and J. G. Cairncross Recent developments in the molecular characterization and treatment of oligodendroglial tumors Neuro-oncol, April 1, 2003; 5(2): 128 - 138. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Quinn, D. A. Reardon, A. H. Friedman, J. N. Rich, J. H. Sampson, J. M. Provenzale, R. E. McLendon, S. Gururangan, D. D. Bigner, J. E. Herndon II, et al. Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma J. Clin. Oncol., February 15, 2003; 21(4): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Lunsford, D. Kondziolka, O. Surma-aho, J. Jaaskelainen, L. M. DeAngelis, and K. Peterson Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients Neurology, December 1, 2001; 57(11): 2150 - 2151. [Full Text] [PDF]
|
|
|
|
|
|
K. Peterson and L. M. DeAngelis Weighing the benefits and risks of radiation therapy for low-grade glioma Neurology, May 22, 2001; 56(10): 1255 - 1256. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. DeAngelis Brain Tumors N. Engl. J. Med., January 11, 2001; 344(2): 114 - 123. [Full Text] [PDF]
|
|
|
|
|
|
J. G. Cairncross Understanding low-grade glioma: A decade of progress Neurology, April 11, 2000; 54(7): 1402 - 1403. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
